Experimental arthritis: Do you want to treat arthritis? IDO2!

Nature Reviews Rheumatology 13, 196 (2017). doi:10.1038/nrrheum.2017.33 Author: Joanna Collison Therapeutically targeting indoleamine 2,3-dioxygenase 2 (IDO2) using a specific monoclonal antibody alleviates experimental arthritis, according to new findings published in Clinical Immunology. “Treatment with anti-IDO2 antibody inhibits autoreactive T and B cell responses and alleviates joint inflammation in the KRN preclinical model of autoimmune

http://feeds.nature.com/~r/nrrheum/rss/current/~3/AoM3IowXIRk/nrrheum.2017.33

Source: Nature Reviews Rheumatology - March 9, 2017 Category: Rheumatology Authors: Joanna Collison Tags: Research Highlight Source Type: research

More News: Allergy & Immunology | Arthritis | Rheumatology